Incyte Corporation (INCY) Presents at Leerink Global Healthcare Conference 2026 Transcript

Core Business Overview - The company estimates that its core business, excluding Jakafi, has the potential to reach sales of approximately $3 billion to $4 billion over the next 5 years [2] - The core business includes FDA-approved marketed products such as Opzelura, Niktimvo, and Monjuvi, which are expected to grow to a size comparable to Jakafi by 2030 [2] - Additional products in the pipeline, including XR and povorcitinib, are anticipated to receive approval within the next 12 months [2] Research and Development Focus - The company has a pipeline of 7 assets, with about 80% of its R&D investment concentrated in the areas of hematology, oncology, and immunology [3]